The @entity1606 ( @entity1606 ) pattern has been associated with favorable outcome in @entity1 with @entity43 who receive chemotherapy. We examined the clinicopathologic significance of @entity1606 and explored other histopathologic prognostic indicators for @entity1 with @entity43 . The surgical records of @entity1 at the University of California at Davis Medical Center who underwent treatment for stages 2 to 4 @entity43 were studied retrospectively; the histopathologic features were correlated with outcome. The @entity1606 pattern was identified in 32 of 136 @entity43 (23.5%): 18 (13.2%) as a predominant (> 50%) and 14 (10.3%) as a focal (< or = 50% but > 25%) histologic pattern. The other predominant histopathologic types were serous (65.4%), mucinous (11.7%), endometrioid (3.6%), clear cell (3.6%), and small cell (1.5%) @entity189 . Architectural grade was as follows: low malignant potential, 13 cases; grade I, 34 cases; grade II, 63 cases; grade III, 26 cases. Nuclear grade was as follows: low grade, 27 cases; high grade, 109 cases. One hundred seven @entity1 @entity43 , and 29 had diffuse primary peritoneal @entity5 . One hundred twenty-three cases (90%) of @entity6378 were invasive; 11 (10%) were noninvasive. @entity6378 histopathologic density was 50% or less cross-sectional involvement in 68 @entity1 (50%) and greater than 50% in 68 (50%). Follow-up data were available for 118 @entity1 : 46 @entity1 had persistent disease that was unresponsive to chemotherapy; 36 of these @entity1 died of disease at 0 to 41 months (mean, 15.6 months; median, 23.5 months). Ten @entity1 were alive at 16 to 40 months (mean, 24.5 months; median, 20.5 months). Thirty-six @entity1 had recurrent disease after 6 to 66 months (mean, 23.5 months; median, 18.5 months); 20 of these @entity1 died of disease after 10 to 69 months (mean, 33.7 months; median, 30 months), and 16 were alive after 12 to 159 months (mean, 33.7 months; median, 30 months). Thirty-six @entity1 had no evidence of disease at 12 to 159 months of follow-up (mean, 49.5 months; median, 31 months). The @entity1606 pattern, either predominant or focal, was not associated with disease status or survival time (P > .05). Predictors of recurrent or persistent disease and survival, respectively, were @entity3906 (P < .05, P < .0001) and greater than 50% cross-sectional area histologic density of @entity6378 (P < .01, P < .01). Grade, histologic type, and diffuse primary peritoneal vs ovarian location were not predictors of outcome. The @entity1606 pattern was present in at least a focal (> 25%) component in 23% of @entity5 ; however, this finding did not reach significance as a predictor of outcome in this study. The histologic pattern of the @entity6378 (invasiveness and density) was a much stronger predictor of disease response and survival.

Clinicopathologic significance of XXXX pattern in nonlocalized @entity43 (stages 2-4).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian epithelial tumors', 'late-stage ovarian epithelial tumors', 'had dominant ovarian tumors', 'ovarian epithelial tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['epithelial tumors', 'epithelial tumor'] @entity3906 :: ('MESH:D010534', 'Disease') :: ['invasive peritoneal disease'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity6378 :: ('MESH:D010532', 'Disease') :: ['Peritoneal disease', 'peritoneal disease'] @entity1606 :: ('MESH:D002295', 'Disease') :: ['transitional cell carcinoma', 'TCC']
@entity1606 :: (MESH:D002295,Disease) :: ['transitional cell carcinoma']
